Search

The Rosalind Franklin Society (RFS) has announced the recipient of the 2023 RFS Award in Science for the journal "Assay & Drug Development Technologies." The award recognizes the outstanding research and published work of women and underrepresented minority scientists, physicians, and engineers. The winning article, titled "Identification of Potent, Selective, and Peripherally Restricted Serotonin Receptor 2B Antagonists from a High-Throughput Screen," discusses the discovery of highly potent and selective 5-HT2B antagonists, which have potential therapeutic applications for pulmonary arterial hypertension and valvular heart disease. The article also highlights two compounds, VU0530244 and VU0631019, that are predicted to have limited potential for brain penetration, making them suitable for the development of 5-HT2B antagonists without centrally-mediated adverse effects. The article is authored by Aaron M. Bender, Michael S. Valentine, Joshua A. Bauer, Emily Days, Craig W. Lindsley, and W. David Merryman. The abstract provides an overview of the research findings, and the biosketch introduces Emily Days, a Data Analyst at the Vanderbilt University High-Throughput Screening Facility, who played a significant role in the awarded project. [Extracted from the article]